Fly News Breaks for December 9, 2019
Dec 9, 2019 | 13:37 EDT
Piper Jaffray analyst Danielle Brill said the one-year follow-up data presented by uniQure on AMT-061, their gene therapy for Hemophilia B, at the ASH meeting "solidify uniQure's front runner status" in the race for a Hem-B gene therapy. Brill, who believes uniQure's AMT-061 is "poised to dominate the Hemophilia B gene therapy market," keeps an Overweight rating on the shares following the presentations at the Annual Meeting of the American Society of Hematology.
News For QURE From the Last 2 Days
There are no results for your query QURE